Status:
COMPLETED
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional study using existing data including medical chart review.
Eligibility Criteria
Inclusion
- Written informed consent prior to participation
- Female and male patients age ≥ 18 years
- Patients with T2D diagnosis
- Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
- Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1
Exclusion
- Patients age \< 18 years
- Patients with diagnosis of other types of diabetes than T2D
- Patients who do not provide written consent to the terms of the study
Key Trial Info
Start Date :
August 26 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
4083 Patients enrolled
Trial Details
Trial ID
NCT03807440
Start Date
August 26 2019
End Date
August 31 2021
Last Update
December 1 2023
Active Locations (177)
Enter a location and click search to find clinical trials sorted by distance.
1
MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903
Byala, Bulgaria, 7100
2
MC "Diamedical 2013" OOD, Center Nr.: 35902
Dimitrovgrad, Bulgaria, 6400
3
MBAL- Dobrich AD, Center Nr.: 35916
Dobrich, Bulgaria, 9300
4
Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904
Dupnitsa, Bulgaria, 2600